Related Experiment Videos
Age-related response to two Haemophilus influenzae type b vaccines
Insights
The Haemophilus influenzae type b (Hib) vaccine PRP-P demonstrated superior immunogenicity and comparable safety to the PRP vaccine in children. Both Hib vaccines were better tolerated than DTP vaccine.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Haemophilus influenzae type b (Hib) infections pose a significant health risk to children.
- Developing effective and safe Hib vaccines is crucial for pediatric public health.
- Assessing vaccine immunogenicity and safety across different age groups is essential for optimal vaccination strategies.
Purpose of the Study:
- To compare the efficacy and safety of two Hib vaccines: polysaccharide (PRP) and polysaccharide-protein conjugate (PRP-P).
- To evaluate the immunogenicity and immunoresponsiveness of PRP and PRP-P vaccines in different pediatric age groups.
- To assess the incidence of side effects associated with PRP, PRP-P, and DTP vaccines.
Main Methods:
- A comparative study involving 71 normal children across three age groups (6-8 months, 15-18 months, 36-72 months).
- Administration of two types of Hib vaccines (PRP and PRP-P) and a control DTP vaccine.
- Measurement of anti-PRP antibody levels and assessment of side effects post-vaccination.
Main Results:
- PRP-P vaccination resulted in higher anti-PRP antibody levels compared to PRP vaccination across all age groups.
- Immunoresponsiveness to both Hib vaccines increased with advancing age.
- PRP and PRP-P vaccines exhibited a lower incidence of side effects (15% and 20%, respectively) compared to the DTP vaccine (56%).
Conclusions:
- The PRP-P vaccine demonstrates greater immunogenicity than the PRP vaccine.
- Both PRP and PRP-P vaccines are well-tolerated in children.
- PRP-P represents a potentially more effective Hib vaccination option for pediatric populations.
Abstract:
Two types of Hib vaccines were compared for efficacy and safety in 71 normal children in three age groups: 36 to 72 months, 15 to 18 months, and 6 to 8 months. One vaccine contained the Hib-specific capsular polysaccharide, PRP; the second vaccine contained PRP combined with pertussis vaccine, PRP-P. A third vaccine, DTP, was administered to a control group for each age. Anti-PRP antibody levels were greater after vaccination with PRP-P than after PRP in all three age groups. Immunoresponsiveness to both vaccines increased with age. A lower incidence of side effects was seen with both PRP (15%) and PRP-P (20%) than with DTP (56%). The results suggest that PRP-P is both well tolerated clinically and has greater immunogenicity than PRP.